[go: up one dir, main page]

HRP20050986A2 - Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof - Google Patents

Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof

Info

Publication number
HRP20050986A2
HRP20050986A2 HR20050986A HRP20050986A HRP20050986A2 HR P20050986 A2 HRP20050986 A2 HR P20050986A2 HR 20050986 A HR20050986 A HR 20050986A HR P20050986 A HRP20050986 A HR P20050986A HR P20050986 A2 HRP20050986 A2 HR P20050986A2
Authority
HR
Croatia
Prior art keywords
mcp
antibodies
antigen
antibodies directed
well
Prior art date
Application number
HR20050986A
Other languages
English (en)
Croatian (hr)
Inventor
Jean
Haak-Frendscho Mary
Foord Orit
Meina
Ahluwalia Kiran
Bhakta Sunil
Original Assignee
Abgenix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31888391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20050986(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abgenix filed Critical Abgenix
Publication of HRP20050986A2 publication Critical patent/HRP20050986A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20050986A 2002-08-19 2003-08-19 Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof HRP20050986A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40480202P 2002-08-19 2002-08-19
PCT/US2003/026232 WO2004016769A2 (en) 2002-08-19 2003-08-19 Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof

Publications (1)

Publication Number Publication Date
HRP20050986A2 true HRP20050986A2 (en) 2006-11-30

Family

ID=31888391

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050986A HRP20050986A2 (en) 2002-08-19 2003-08-19 Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof

Country Status (17)

Country Link
US (3) US7202343B2 (is)
EP (1) EP1542724A4 (is)
JP (1) JP4468172B2 (is)
AU (1) AU2003265575B2 (is)
CA (1) CA2496419A1 (is)
CO (1) CO6220978A2 (is)
HR (1) HRP20050986A2 (is)
IL (1) IL171674A0 (is)
IS (1) IS8115A (is)
LT (1) LT5416B (is)
ME (1) MEP18108A (is)
NZ (1) NZ542784A (is)
RS (1) RS20050834A (is)
RU (1) RU2339647C2 (is)
UA (1) UA87979C2 (is)
WO (1) WO2004016769A2 (is)
ZA (1) ZA200508994B (is)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094595B2 (en) * 2000-10-30 2006-08-22 Sru Biosystems, Inc. Label-free high-throughput optical technique for detecting biomolecular interactions
US7575939B2 (en) 2000-10-30 2009-08-18 Sru Biosystems, Inc. Optical detection of label-free biomolecular interactions using microreplicated plastic sensor elements
CN104178491B (zh) 2002-09-06 2018-07-03 安姆根有限公司 治疗性人抗-il-1r1单克隆抗体
US7927822B2 (en) 2002-09-09 2011-04-19 Sru Biosystems, Inc. Methods for screening cells and antibodies
WO2004080273A2 (en) 2003-03-12 2004-09-23 Rappaport Family Institute For Research In The Medical Sciences Compositions and methods for diagnosing and treating prostate cancer
US8017113B2 (en) 2003-03-12 2011-09-13 Rappaport Family Institute For Research In The Medical Sciences Compositions and methods for diagnosing and treating an inflammation
CA2544924A1 (en) * 2003-11-05 2005-05-19 Centocor, Inc. Methods and compositions for treating mcp-1 related pathologies
US7674884B2 (en) * 2003-12-10 2010-03-09 Novimmune S.A. Neutralizing antibodies and methods of use thereof
US8481035B2 (en) * 2004-04-27 2013-07-09 Northwestern University Methods for treating chronic pelvic pain syndrome with antibodies that binds MCP-1 or MIP-1A
US7794949B2 (en) * 2004-04-27 2010-09-14 Northwestern University Biomarkers of chronic pelvic pain syndrome
ES2344793T3 (es) 2004-08-05 2010-09-07 Genentech, Inc. Antagonistas anti-cmet humanizados.
PA8675801A1 (es) * 2005-05-19 2006-12-07 Centocor Inc Anticuerpos anti-mcp-1, composiciones, metodos y usos
US8114964B2 (en) * 2005-05-19 2012-02-14 Centocor, Inc. Anti-MCP-1 antibodies, compositions, methods and uses
US20070099239A1 (en) * 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
EP1926747A1 (en) * 2005-08-12 2008-06-04 Schering Corporation Mcp1 fusions
EP1989216A4 (en) * 2006-03-01 2010-03-31 Univ Michigan DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
WO2007140316A1 (en) * 2006-05-26 2007-12-06 Board Of Regents, The University Of Texas System Reverse phase protein array, protein activation and expression signatures, and associated methods
US20090297502A1 (en) * 2006-06-15 2009-12-03 Li Li Ccr2 antagonists for chronic organ transplantation rejection
JP2009544690A (ja) * 2006-07-24 2009-12-17 イェダ リサーチ アンド デベロップメント カンパニー リミテッド Ｃｃｌ２を含む医薬組成物および炎症の処置のためのその使用
CA2672944A1 (en) 2006-12-22 2008-07-03 Ablynx N.V. Amino acid sequences directed against chemokines and polypeptides comprising the same for the treatment of chemokine-related diseases and disorders
EP1958647A1 (en) * 2007-02-15 2008-08-20 Helmholtz-Zentrum für Infektionsforschung GmbH Pharmaceutical composition with bacteria for tumor treatment
CN101827610A (zh) * 2007-06-29 2010-09-08 森托科尔奥索生物科技公司 抗mcp-1抗体、组合物、方法和用途
US9778267B2 (en) 2007-07-11 2017-10-03 X-Body, Inc. Methods for identifying modulators of ion channels
US9134307B2 (en) 2007-07-11 2015-09-15 X-Body, Inc. Method for determining ion channel modulating properties of a test reagent
AU2008287037B2 (en) * 2007-08-10 2013-10-10 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
JP5641599B2 (ja) * 2007-08-24 2014-12-17 学校法人慶應義塾 腫瘍細胞による免疫抑制の解除剤とそれを用いた抗腫瘍剤
US9855370B2 (en) * 2008-01-08 2018-01-02 Yale University Compositions and methods for promoting patency of vascular grafts
US8257936B2 (en) 2008-04-09 2012-09-04 X-Body Inc. High resolution label free analysis of cellular properties
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
CN102076355B (zh) * 2008-04-29 2014-05-07 Abbvie公司 双重可变结构域免疫球蛋白及其用途
TW201008580A (en) * 2008-06-03 2010-03-01 Abbott Lab Dual variable domain immunoglobulin and uses thereof
US9109026B2 (en) * 2008-06-03 2015-08-18 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
JP5674654B2 (ja) * 2008-07-08 2015-02-25 アッヴィ・インコーポレイテッド プロスタグランジンｅ２二重可変ドメイン免疫グロブリンおよびその使用
CN102239180B (zh) 2008-08-18 2014-12-31 辉瑞大药厂 抗ccr2抗体
NZ591187A (en) * 2008-08-20 2012-07-27 Probiodrug Ag Antibodies directed against pyroglutamate monocyte chemoattractant protein-1 (mcp-1 n1pe)
US8262879B2 (en) 2008-09-03 2012-09-11 Nabsys, Inc. Devices and methods for determining the length of biopolymers and distances between probes bound thereto
MX2011003855A (es) * 2008-10-22 2011-12-16 Inst Research In Biomedicine Metodos para producir anticuerpos a partir de celulas plasmaticas.
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
RU2393216C1 (ru) * 2009-02-06 2010-06-27 Александр Валентинович Шишкин Способ комбинированного иммунологического исследования клеток с помощью биочипа
MX2011009897A (es) 2009-03-20 2011-12-08 Amgen Inc Anticuerpo de antagonista especifico de heterodimero alfa-4-beta-7.
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
AU2010286516B2 (en) 2009-08-28 2016-10-06 Regeneron Pharmaceuticals, Inc. Antikine antibodies that bind to multiple CC chemokines
NZ598929A (en) * 2009-09-01 2014-05-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
BR112012008833A2 (pt) * 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CN102947705A (zh) * 2010-02-18 2013-02-27 前体生物药物股份公司 通过确定焦谷氨酸修饰的mcp-1诊断炎性疾病的方法和谷氨酰胺酰基环化酶抑制剂的筛选方法
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
PE20131412A1 (es) 2010-08-03 2014-01-19 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2608803A4 (en) 2010-08-26 2014-01-15 Abbvie Inc IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
AU2012239997A1 (en) * 2011-04-07 2013-10-17 Amgen Inc. Novel EGFR binding proteins
KR20140045440A (ko) 2011-06-30 2014-04-16 제넨테크, 인크. 항-c-met 항체 제제
UY34558A (es) 2011-12-30 2013-07-31 Abbvie Inc Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
UY34813A (es) 2012-05-18 2013-11-29 Amgen Inc Proteínas de unión a antígeno dirigidas contra el receptor st2
RU2501017C1 (ru) * 2012-10-18 2013-12-10 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский институт акушерства и педиатрии" Министерства здравоохранения и социального развития Российской Федерации Способ прогнозирования невынашивания беременности в ранние сроки
KR20190096459A (ko) 2012-11-01 2019-08-19 애브비 인코포레이티드 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
BR112015023797A2 (pt) 2013-03-15 2017-10-24 Abbvie Inc proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
HK1219891A1 (zh) * 2013-08-06 2017-04-21 国立大学法人九州大学 有机酸聚合物作为有效组分的、预防或抑制癌细胞生存的药物
EP3041863A4 (en) 2013-09-05 2017-08-16 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
WO2015148531A1 (en) 2014-03-24 2015-10-01 Genentech, Inc. Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
EP3143404B1 (en) 2014-05-16 2018-08-29 Amgen Inc. Assay for detecting th1 and th2 cell populations
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
JP6957468B2 (ja) 2015-12-11 2021-11-02 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 最適化された患者特異的組織操作血管移植片のためのシステムおよび方法
CA3029074A1 (en) 2016-06-22 2018-01-25 William Warren HARLESS Cancer treatment and metastasis inhibition using an anti-cancer stem cell agent in combination with a neu1 sialidase inhibitor or a cytokine inhibitor after primary cancer treatment
EP4252629A3 (en) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
EP3554541B1 (en) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
KR20190118172A (ko) 2017-02-08 2019-10-17 드래곤플라이 쎄라퓨틱스, 인크. 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도
EP3579866A4 (en) * 2017-02-08 2020-12-09 Dragonfly Therapeutics, Inc. VARIABLE DOMAINS OF ANTIBODY HEAVY CHAINS TARGETING THE NKG2D RECEIVER
JP7685821B2 (ja) 2017-02-20 2025-05-30 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｈｅｒ２、ＮＫＧ２ＤおよびＣＤ１６に結合するタンパク質
US12503700B2 (en) 2017-03-14 2025-12-23 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
CN108048408B (zh) * 2018-01-26 2020-02-07 扬州大学 牛单核细胞趋化蛋白-1杂交瘤细胞株、其分泌的单克隆抗体及应用
DK3749346T3 (da) 2018-02-08 2024-09-09 Dragonfly Therapeutics Inc Antistof variable domænekombinationer rettet mod nkg2d-receptoren
CN112040971A (zh) 2018-02-08 2020-12-04 蜻蜓疗法股份有限公司 涉及激活天然杀伤细胞的多特异性结合蛋白的癌症联合疗法
TW201942134A (zh) 2018-02-20 2019-11-01 美商蜻蜓醫療公司 結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法
US12325737B2 (en) 2018-03-26 2025-06-10 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
AU2019318083A1 (en) 2018-08-08 2021-02-25 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
KR20250112921A (ko) 2018-08-08 2025-07-24 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
AR118898A1 (es) * 2019-05-09 2021-11-10 Merus Nv Dominios variantes para multimerizar proteínas y su separación
CN114450593A (zh) 2019-09-26 2022-05-06 美国安进公司 产生抗体组合物的方法
EP4309722A3 (en) 2019-12-13 2024-08-07 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP4146271A4 (en) 2020-05-06 2024-09-04 Dragonfly Therapeutics, Inc. PROTEINS THAT BIND NKG2D, CD16 AND CLEC12A
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
JP2023548767A (ja) 2020-10-15 2023-11-21 アムジエン・インコーポレーテツド 抗体製造方法における相対不対グリカン
CN117222663A (zh) 2021-03-03 2023-12-12 蜻蜓疗法股份有限公司 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法
EP4352094A1 (en) 2021-06-07 2024-04-17 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
US20250076309A1 (en) 2021-10-05 2025-03-06 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023122211A2 (en) * 2021-12-21 2023-06-29 Duke University Coronavirus antibodies and uses thereof
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2023213400A1 (en) * 2022-05-05 2023-11-09 Institute For Research In Biomedicine Antibodies against chemokines, method for identifying said antibodies and uses thereof
AU2024256160A1 (en) 2023-04-20 2025-10-02 Amgen Inc. Methods of determining relative unpaired glycan content
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
JPH0967399A (ja) * 1995-08-30 1997-03-11 Mitsui Toatsu Chem Inc 抗ｍｃｐ−１ヒトモノクローナル抗体
AU711626B2 (en) * 1995-09-27 1999-10-21 Shionogi & Co., Ltd. Type CC chemokine-like protein
JPH1160502A (ja) * 1997-08-12 1999-03-02 Teijin Ltd 脳梗塞症治療薬もしくは予防薬
AU6174301A (en) * 2000-05-19 2001-12-03 Us Health Methods for reducing tumor growth and metastasis by inhibiting mcp-1 activity
GB0016138D0 (en) * 2000-06-30 2000-08-23 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
EP1542724A4 (en) 2005-10-19
US20050058639A1 (en) 2005-03-17
US7482434B2 (en) 2009-01-27
CA2496419A1 (en) 2004-02-26
MEP18108A (en) 2010-06-10
IS8115A (is) 2005-11-01
EP1542724A2 (en) 2005-06-22
WO2004016769A2 (en) 2004-02-26
RU2339647C2 (ru) 2008-11-27
US7202343B2 (en) 2007-04-10
LT5416B (lt) 2007-04-25
JP2005536534A (ja) 2005-12-02
CO6220978A2 (es) 2010-11-19
US7687606B2 (en) 2010-03-30
ZA200508994B (en) 2006-09-27
WO2004016769A3 (en) 2004-10-14
AU2003265575A1 (en) 2004-03-03
RS20050834A (sr) 2007-12-31
NZ542784A (en) 2008-07-31
RU2005134354A (ru) 2006-06-10
LT2005099A (en) 2006-11-27
US20070116708A1 (en) 2007-05-24
US20070128112A1 (en) 2007-06-07
IL171674A0 (en) 2009-02-11
UA87979C2 (ru) 2009-09-10
AU2003265575B2 (en) 2009-12-10
JP4468172B2 (ja) 2010-05-26

Similar Documents

Publication Publication Date Title
HRP20050986A2 (en) Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
NO20076673L (no) Antistoffer rettet mot CD20 og anvendelser derav
AR052065A1 (es) Anticuerpos dirigidos contra angiopoyetina-2 y usos de los mismos
AR062213A1 (es) Anticuerpos dirigidos contra (alfa v beta 6) y usos de los mismos
NO20066052L (no) Anti-CD3 antistoffer og fremgangsmater for anvendelse derav
TW200637873A (en) Antibodies against interleukin-1 beta
HRP20010551B1 (hr) Humana monoklonalna antitijela za ctla-4
DE60333228D1 (de) Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
WO2007120693A3 (en) Targeted binding agents directed to upar and uses thereof
HRP20020693B1 (hr) HUMANIZIRANA PROTUTIJELA KOJA SADRŽE PEPTID Aß
CO5660296A2 (es) Anticuerpos humanizados que reconocen el peptido beta amiloide
WO2003057857A3 (en) Antibodies directed to pdgfd and uses thereof
PE20050925A1 (es) Anticuerpo recombinante humanizado anti-interleuquina 10
DK1414858T3 (da) Kamelid-enkeltkæde-VHH-antistoffer, fremgangsmåde til fremstilling heraf i et pattedyr samt anvendelser heraf
BR0318454A (pt) anticorpos dirigidos a hormÈnio da paratireóide (pth) e seus usos
PE20030846A1 (es) Anticuerpos para cd40
EA200501756A1 (ru) Химерные гибриды мономер-димер иммуноглобулина
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
WO2007109307A3 (en) Antibodies directed to angiopoietin-like protein 4 and uses thereof
BR0207151A (pt) Moléculas de aglutinação terapêuticas
MX2025004739A (es) Anticuerpo anti-cd16a y aplicacion del mismo
TH94700A (th) แอนติบอดีที่มุ่งต่อ cd20 และการใช้ของมัน

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
PPPP Transfer of rights

Owner name: AMGEN FREMONT INC., US

Owner name: ASTRAZENECA AB, SE

RESP Petition for restitutio in integrum
RESU Restitutio in integrum adopted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20090811

Year of fee payment: 7

OBST Application withdrawn